Literature summary for 1.8.98.2 extracted from

Findlay, V.J.; Tapiero, H.; Townsend, D.M.
Sulfiredoxin: a potential therapeutic agent? (2005), Biomed. Pharmacother., 59, 374-379.

Search for more literature for 1.8.98.2

Natural Substrates/ Products (Substrates)

Natural Substrates	Organism	Comment (Nat. Sub.)	Natural Products	Comment (Nat. Pro.)	Rev.	Reac.
peroxiredoxin-(S-hydroxy-S-oxocysteine) + ATP + 2 R-SH	Homo sapiens	antioxidant protein with a role in signaling through catalytic reduction of oxidative modifications. Srx also has a role in the reduction of glutathionylation a post-translational, oxidative modification that occurs on numerous proteins and has been implicated in a wide variety of pathologies, including Parkinsonâs disease. Unlike the reduction of peroxiredoxin overoxidation, Srx-dependent deglutathionylation appears to be nonspecific	peroxiredoxin-(S-hydroxycysteine) + ADP + phosphate + R-S-S-R	-	?

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
peroxiredoxin-(S-hydroxy-S-oxocysteine) + ATP + 2 R-SH	antioxidant protein with a role in signaling through catalytic reduction of oxidative modifications. Srx also has a role in the reduction of glutathionylation a post-translational, oxidative modification that occurs on numerous proteins and has been implicated in a wide variety of pathologies, including Parkinsonâs disease. Unlike the reduction of peroxiredoxin overoxidation, Srx-dependent deglutathionylation appears to be nonspecific	Homo sapiens	peroxiredoxin-(S-hydroxycysteine) + ADP + phosphate + R-S-S-R	-	?

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)